Our Platforms
Transpire Bio unlocks clinical value through inhalation technology
We aim to improve outcomes for diseases and conditions with unmet needs by applying our deep inhalation expertise and patented formulation and delivery platforms to drugs with a known mechanism of action, creating new therapeutic opportunities.
Transpire Bio unlocks clinical value through inhalation technology
We aim to improve outcomes for diseases and conditions with unmet needs by applying our deep inhalation expertise and patented formulation and delivery platforms to drugs with a known mechanism of action, creating new therapeutic opportunities.
Fully developed, advanced inhalation platforms
These platforms are powered by a $60+ million state-of-the-art, US-based R&D/pilot cGMP manufacturing facilities investment and 139,000 square feet of high-volume manufacturing capacity (under construction).
Our platforms enable multiple opportunities
We are actively advancing initiatives in three strategic areas to maximize short-term and long-term clinical and economic value:
Innovative biopharmaceuticals
We are advancing in-house innovative therapies for high-potential lung disease, CNS, oncology, and obesity markets.
Co-development partnerships
We are pursuing and engaging with strategic pharmaceutical partners to rapidly advance innovative inhaled therapies together.
Complex generics
We are developing early-to-market, difficult-to-replicate asthma/COPD generic inhaled therapies, and partnering for their commercialization.
